Isabella Ciccone, M.P.H.

The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.

Researchers in Serbia identified link between autonomic symptom burden and quality of life.